Emergency funds for 16 cities

September 1991
FDA Consumer;Sep91, Vol. 25 Issue 7, p9
Announces that emergency funds totaling $43 million will go to 16 United States cities hit particularly hard by the AIDS epidemic. The funds will support health and social services for people with AIDS and HIV disease. Details on recipients.


Related Articles

  • PAYING FOR AIDS. Poser, Carla; Masland, Tom; Pan, Esther; Santoro, Lara; Moreau, Ron; Margolis, Mac // Newsweek (Atlantic Edition);03/19/2001 (Atlantic Edition), Vol. 137 Issue 12, p16 

    Discusses the cost of AIDS drugs in the developing world. Reduction of drug costs in Africa by pharmaceutical companies; Comment by GlacoSmithKline chief executive officer Jean-Pierre Garnier that the company should not cater to the rich, but give medicine to those that need it; Concerns of...

  • A Question of Access.  // Newsweek (Atlantic Edition);07/24/2000 (Atlantic Edition), Vol. 136 Issue 4, p44 

    Offers an interview with Jeffrey Sturchio, Merck & Co.'s executive director for public affairs in Europe, the Middle East and Africa, on the subject of pricing of AIDS drugs. His belief that even if AIDS drugs were free, there would still be a problem in providing access for everyone;...

  • Sports groups review HIV policies. A.S. // Physician & Sportsmedicine;Nov92, Vol. 20 Issue 11, p15 

    Lists medical and sports organizations addressing questions and public's concerns on the human immunodeficiency virus (HIV). American Medical Society for Sports Medicine in Middleton, Wis.; American Orthopaedic Society for Sports Medicine in Des Plaines, Ill.; American College of Sports Medicine...

  • Towards a vaccine against AIDS. Vieillard, Vincent; Dereuddre-Bosquet, Nathalie; Corneau, Aurélien; Mangeot-Méderle, Isabelle; Fausther-Bovendo, Hugues; Grand, Roger Le; Debre, Patrice // Retrovirology;2010 Supplement 1, Vol. 7, p1 

    An abstract of the article "Towards a Vaccine Against AIDS," by Vincent Vieillard, Nathalie Dereuddre-Bosquet, Aurélien Corneau, Isabelle Mangeot-Méderle, Hugues Fausther-Bovendo, Roger Le Grand and Patrice Debre is presented.

  • AIDS as a clinically curable disease: The growing optimism. Gallo, Robert C. // AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p7 

    Suggest that AIDS might be a clinically curable disease. Effects of chemotherapy; Advances in chemotherapy compared with other HIV enzymes; Replication of HIV; Approaches to minimizing toxicity.

  • Didanosine toxicity.  // AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p50 

    Reports on the tolerance of AIDS patients to the drug didanosine. Toxicity of didanosine; Comparison to other drugs; What studies have shown.

  • Editorial. Laurence, Jeffrey // AIDS Patient Care & STDs;Aug96, Vol. 10 Issue 4, p208 

    Editorial. Comments on the effects of the prolonged drug development and approval processes on the growing incidence of AIDS among women in the United States. Wider availability of novel agents early in drug development; Unrecognized sexually transmitted diseases as a cause of marked increase...

  • Editorial. Laurence, Jeffrey // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p278 

    Editorial. Expresses concern and hope on the developments of AIDS treatment based on reports in the Eleventh International AIDS Conference. Longer lives for compliant users of multidrug antiviral regimens; Absence of documented complete destruction of virus; Treatment costs as enormous;...

  • Public policy update: An AmFAR report. Silver, Jane // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p304 

    Features the AIDS Drug Assistance Program (ADAP), a prescription drug reimbursement programs for Americans with HIV/AIDS. History of ADAP and its goals; Funds from support groups; Need for additional federal funding; Medical insurance coverages as the only recourse upon implementation of Health...

  • Triple therapy in previously untreated patients reduces viral load below limit of detection.  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p308 

    Presents results of triple drug regimen in previously untreated AIDS patients. Sustained one year reduction in viral load below levels of detection; Use of protease inhibitors not absolutely necessary; Significant improvements in CD4 cell counts; Percentage of mild to moderate rashes in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics